Corbus Pharmaceuticals Holdings is a clinical-stage pharmaceutical company. Co.'s pipeline includes the following programs: Lenabasum, a synthetic, oral, cannabinoid receptor type 2 (CB2) agonist designed to resolve chronic inflammation, limit fibrosis and support tissue repair; Peripherally-restricted cannabinoid receptor type 1 (CB1) inverse agonists designed to normalize metabolic abnormalities or limit inflammation and fibrosis; and CB2 agonists designed to limit cancer cell growth directly and reduce the fibrosis and immunosuppression in the tumor microenvironment that are related with tumor growth, metastasis, and resistance to treatment with drugs such as checkpoint inhibitors. The CRBP stock yearly return is shown above.
The yearly return on the CRBP stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2020 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the CRBP annual return calculation with any dividends reinvested as applicable (on ex-dates).
|